Table 13:
Total Costs and Net Budget Impact for an Increasing Uptake Rate for SCIG Versus a Continued Current Uptake Rate in Ontario, Scenario Analyses
| Uptake Rate of SCIG | Results ($) | |||||
|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | ||
| Scenario analysis 1: societal perspective | ||||||
| Total cost of SCIG and IVIG | Current: 22% | 24,391,250 | 26,256,156 | 28,363,124 | 30,646,092 | 33,091,502 |
| Increasing | 23,796,653 | 25,303,565 | 27,077,521 | 28,974,317 | 31,032,138 | |
| Net budget impact | –594,597 | –952,591 | –1,285,603 | –1,671,775 | –2,059,364 | |
| Scenario analysis 2: higher dose for SCIG (IVIG is the same as the base case) | ||||||
| Total cost of SCIG and IVIG | Current: 22% | 22,797,537 | 24,538,321 | 26,502,777 | 28,637,602 | 30,922,940 |
| Increasing | 23,817,500 | 25,903,656 | 28,347,185 | 31,015,153 | 33,856,248 | |
| Net budget impact | 1,019,963 | 1,365,335 | 1,844,408 | 2,377,551 | 2,933,308 | |
| Scenario analysis 3: nursing time only | ||||||
| Total nursing hours of RARP and ORP | Current: 22% | 23,749 | 24,351 | 26,312 | 28,427 | 30,696 |
| Increasing | 21,335 | 19,209 | 19,373 | 19,440 | 19,617 | |
| Difference in nursing hours | –2,414 | –5,142 | –6,939 | –8,987 | –11,079 | |
| Total cost of SCIG and IVIG | Current: 22% | 1,398,274 | 1,433,709 | 1,549,165 | 1,673,689 | 1,807,279 |
| Increasing | 1,256,160 | 1,130,973 | 1,140,601 | 1,144,551 | 1,154,965 | |
| Net budget impact | –142,114 | –302,736 | –408,564 | –529,138 | –652,314 | |
| Scenario analysis 4: SCIG infusion supplies fully paid by Ministry (IVIG is the same as the base case) | ||||||
| Total cost of SCIG and IVIG | Current: 22% | 21,613,986 | 23,258,069 | 25,123,678 | 27,146,401 | 29,312,357 |
| Increasing | 21,473,078 | 22,957,192 | 24,717,378 | 26,613,425 | 28,656,929 | |
| Net budget impact | –140,907 | –300,878 | –406,301 | –532,976 | –655,428 | |
| Scenario analysis 5: increased number of target population, 60% immunodeficiency patients in Ontario | ||||||
| Total cost of SCIG and IVIG | Current: 22% | 34,922,948 | 37,593,558 | 40,598,782 | 43,851,324 | 47,359,792 |
| Increasing | 34,215,309 | 36,422,816 | 39,021,229 | 41,805,116 | 44,834,563 | |
| Net budget impact | –707,639 | –1,170,743 | –1,577,554 | –2,046,208 | –2,525,230 | |
Abbreviations: IVIG, hospital-based intravenous immunoglobulin; SCIG, home-based subcutaneous immunoglobulin.
Note: Numbers may appear inexact because of rounding.